Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-157 | Cabozantinib | VEGFR2/MET | RTK | 2.7778 | 0.1490 | 0.2101 | 0.0326 | 0.5335 | 21.7804 | 0.97157 |
MDA-MB-361 | Abemaciclib | CDK4/6 | Cell cycle | 0.0053492 | -0.3418 | 0.8279 | 0.0335 | 0.5371 | 0.0096902 | 0.8686 |
MDA-MB-361 | Palbociclib | CDK4/6 | Cell cycle | 0.019625 | 0.1481 | 0.4822 | 0.0065 | 2.1670 | 0.01672 | 0.99444 |
MDA-MB-361 | AZD7762 | CHK1/2 | Cell cycle | 0.0076402 | -0.6753 | 1.0533 | 0.2116 | 2.0458 | 0.010426 | 0.97675 |
MDA-MB-361 | Volasertib | PLK | Cell cycle | 0.0035439 | -0.4972 | 0.8204 | 0.1921 | 4.6311 | 0.0040451 | 0.98886 |
MDA-MB-361 | Dinaciclib | pan CDK | Cell cycle | 0.011817 | -0.2748 | 0.6004 | 0.0836 | 5.0000 | 0.013067 | 0.99187 |
MDA-MB-361 | Cisplatin | Chemo | Chemotherapy | 2.6294 | -0.3498 | 0.1809 | 0.0253 | 2.1659 | 3.6196 | 0.98908 |
MDA-MB-361 | Doxorubicin | Chemo | Chemotherapy | 0.012289 | -0.7224 | 0.9125 | 0.1900 | 2.1676 | 0.017167 | 0.96442 |
MDA-MB-361 | Taxol | Chemo | Chemotherapy | 0.0031082 | -0.6090 | 0.9738 | 0.2561 | 2.5508 | 0.0042111 | 0.9201 |
MDA-MB-361 | Topotecan | Topo I | Chemotherapy | 0.011361 | -0.7622 | 1.1276 | 0.2239 | 1.9673 | 0.01715 | 0.98983 |
MDA-MB-361 | Etoposide | Topo II | Chemotherapy | 1.1915 | -0.5173 | 0.3432 | 0.0513 | 1.6855 | 1.9175 | 0.9862 |
MDA-MB-361 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.26737 | 0.0805 | 0.3513 | 0.0255 | 1.3524 | 0.20359 | 0.98324 |
MDA-MB-361 | Trametinib | MEK | MAPK/nRTK | 1.0029 | 0.5021 | 0.2191 | 0.0194 | 0.4857 | 0.060413 | 0.90885 |
MDA-MB-361 | Saracatinib | SRC | MAPK/nRTK | 0.42599 | -0.1780 | 0.4058 | 0.0330 | 0.4194 | 5.848 | 0.98077 |
MDA-MB-361 | ABT-737 | Bcl2/XL | Misc | Inf | 0.8441 | -0.0067 | 0.0094 | 2.5452 | 4.5021 | 0.68512 |
MDA-MB-361 | Vorinostat | HDAC | Misc | 0.76224 | -0.9392 | 0.4607 | 0.1761 | 2.2187 | 1.2401 | 0.99784 |
MDA-MB-361 | Luminespib | HSP90 | Misc | 0.0071417 | -0.8855 | 0.9781 | 0.3455 | 4.9987 | 0.0087421 | 0.9995 |
MDA-MB-361 | A-1210477 | Mcl-1 | Misc | Inf | 0.9850 | -0.0083 | 0.0037 | 0.0000 | Inf | -0.045307 |
MDA-MB-361 | Olaparib | PARP | Misc | 4.8624 | 0.0945 | 0.1038 | 0.0095 | 1.2844 | 11.0203 | 0.97233 |
MDA-MB-361 | Bleomycin | Radiation | Misc | 0.75794 | -0.2660 | 0.3607 | 0.0429 | 0.8418 | 1.9803 | 0.97757 |
MDA-MB-361 | Ipatasertib | AKT | PI3K/mTOR | 0.31325 | -0.5798 | 0.4548 | 0.0905 | 0.7404 | 1.2042 | 0.98932 |
MDA-MB-361 | Alpelisib | PI3Ka | PI3K/mTOR | 0.22264 | -0.7994 | 0.5323 | 0.1181 | 0.6802 | 1.1196 | 0.97671 |
MDA-MB-361 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0017737 | -0.9902 | 1.4103 | 0.4329 | 0.6207 | 0.010237 | 0.9975 |
MDA-MB-361 | TGX221 | PI3Kb | PI3K/mTOR | 13.225 | 0.7989 | -0.0336 | 0.0006 | 4.9995 | 13.1104 | 0.64936 |
MDA-MB-361 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0050713 | -0.9642 | 0.8689 | 0.2561 | 0.9911 | 0.014575 | 0.99687 |